# Dasatinib + Quercetin (D+Q)

D+Q is one of the most-studied senolytic combinations. It pairs dasatinib (a tyrosine-kinase-inhibitor cancer drug) with quercetin (a plant flavonoid). You take it intermittently, and it is designed to selectively clear or reduce your senescent ('zombie') cells. In aged mice, it improves physical function and tissue health. Human data are limited to small pilot trials, in lung fibrosis (IPF), diabetic kidney disease, and frailty. Those trials have shown drops in senescence markers. But its value as an anti-aging therapy is unproven, and the use is off-label. D+Q now shares the senolytic field with newer programs. One is Unity Biotechnology's UBX1325 (foselutoclax). It reported peer-reviewed BEHOLD data in NEJM Evidence in April 2025, and later 36-week Phase 2b ASPIRE data by company press release in May 2025.

## Sources

- Justice JN, Nambiar AM, Tchkonia T et al.. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. https://doi.org/10.1016/j.ebiom.2018.12.052
- Hickson LJ, Langhi Prata LGP, Bobart SA et al.. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. https://doi.org/10.1016/j.ebiom.2019.08.069

---

_Canonical: https://longevity-switzerland.com/en/glossary/dasatinib-quercetin · Part of Longevity Cities · Updated 2026-06-22_